Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Authors : Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang ., Wu X, Yao Y, Shen ., Kojima T, Gotovkin, E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca. P, Lin CY (林振源), Wang L, Shi J, Li L, Yoon HH.

Journal : Lancet Oncol

Publication Date : 2023

Image Source : Lancet Oncol

Link : https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00108-0/abstract